ACDN-01
Phase 2Small molecule
ACDN-01 is one of 7 small molecule programs targeting Retinopathy. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Retinopathy
#DrugCompanyPhaseTrials
1Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Tricor
JJagotec
Approved
Betadine
BBecton, Dickinson and Company
Approved
Glucophage
EMD SeronoPhase 2
ACDN-01
AAscidian Therapeutics, Inc
Phase 2
Breast Milk
KKarabuk University
Preclinical
Intravitreal Ranibizumabe
UUniversity of Sao Paulo
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ACDN-01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAscidian Therapeutics, Inc